Antiviral Combination Therapies Market by Drug Combination (Nucleoside Reverse Transcriptase Inhibitor (NTRI)/ Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), NRTI/Protease Inhibitor, Integrase Inhibitor/NRTI, Others) by Indication (Human Immunodeficiency Virus (HIV), Hepatitis, Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2026

Description

The antiviral combination therapies market is set for a rapid growth over the forecast period. In terms of revenue, the global antiviral combination therapies market accounted for USD 40.94 Billion in 2019 and is expected to reach USD 70.03 Billion by 2026, growing at a CAGR of 7.97%

Global Antiviral Combination Therapies Market: Overview

Antiviral combination therapies are medications formulated using a combination of two or more drugs to treat different viral diseases, including chronic infections such as hepatitis B, hepatitis C and Human Immunodeficiency Virus (HIV). Combination antiretroviral treatment aims to stop the virus from producing several copies of itself in the body.

The clinical progress of HIV-infected patients is minimal, despite some developments in combined antiretroviral treatment. In response to therapy, the development of drug-resistant genetic changes plays a crucial role in therapeutic failure and it is considered difficult to discover a new potent drug combination after treatment failure.

Factors that drive the market include the uptick in research and development funding for the advancement of combination medicines that help combat antiviral resistance, the rise in demand for antiviral combinations for HIV treatment, the growth in the occurrence of viral diseases, and the increase in emphasis on the development of vaccines to combat the COVID-19 pandemic

Global Antiviral Combination Therapies Market: Growth Factors

Ongoing investment by major manufacturers in research and development activities in order to create combination drugs that help combat antiviral resistance is also boosting the outlook of the global antiviral combination therapy industry. Boehringer Ingelheim recently announced its intentions to invest about 65 million in Lyon Porte-des-Alpes, France, in an attempt to satisfy the growing need for avian vaccines worldwide.

In addition, the emphasis among leading companies on business-centric activities such as joint ventures, mergers and acquisitions, and ground-breaking product launches also adds momentum to the size of the global antiviral combination therapy industry. However, the stringent regulatory outlook could potentially serve as a deterrent to the overall expansion of the market.

Impact due to the outbreak of COVID-19

Companies are taking bold moves in the antiviral combination therapy market by increasing their paths to tackle COVID-19. In order to innovate in coronavirus combination therapies, the Indian Institute of Chemical Technology (IICT) has teamed up with the Indian subsidiary of the global pharmaceutical company, Mylan. With the assistance of computer modelling of molecules and laboratory evidence, several pharmaceutical companies in India have reached phase 3 of clinical trials. Innovations in combination therapy trials have been fuelled by the increasing demand for antiviral drugs. In addition, growing cases of COVID-19 in India serve as a key driver for business development.

Medical organizations are speeding up efforts to partner with hospitals in combination therapy trials to evolve. The combination of antiviral medicines with antibiotics has been shown to have positive potential for patients to reduce coronavirus symptoms.

Global Antiviral Combination Therapies Market: Segmentation

The integrase inhibitor/NRTI of drug combination segment is expected to account for a substantial share of the global demand for antiviral combination therapies in the near future. This can be due to a rise in the use of this drug combination in HIV care. In addition, the segment is motivated by the patent exclusivity of these drugs.

On the basis of indication, the global market for antiviral combination therapies has been categorized into HIV, hepatitis and others. Worldwide, more than 38 million people were living with HIV in 2019. Of these, about 36.2 million were adults and 1.8 million were children. In addition, more than 1.7 million people became infected with HIV in 2019.

Chronic hepatitis B is a major cause of cirrhosis and hepatocellular carcinoma (HCC) globally. In order to prevent the infection rate of HCC, companies in the market for antiviral combination therapies are increasing the volume of nucleoside analogues or pegylated interferon in effort to stop the progression of cirrhosis. Antiviral combination therapy is widely publicized as an ingredient and a synergistic agent to help avoid HCC in hepatitis B patients. As a result, antiviral combination therapy market players are growing their research to identify the pattern of treatments that can be efficient in reducing HCC in CHB patients.

Global Antiviral Combination Therapies Market: Regional Analysis

By Geography, the antiviral combination therapies market is segmented into North America, Europe, Latin America, Asia Pacific, and Middle East and Africa.

North America was the largest market for antiviral combination therapies in terms of revenue in 2019, and the trend is expected to continue in the coming years. The market in the region is anticipated to grow at a significant rate from 2020 to 2026. Overall growth in North America can be due to an increase in the prevalence of HIV and hepatitis infections among people. In addition, good sales of generic drugs for HIV care led to high revenues from the region in 2019. In addition, patent protection of drugs is expected to contribute to the growth of the market during the forecast period.

The demand for antiviral combination therapies in Asia Pacific is projected to rise at the fastest pace from 2020 to 2026. Development in the demand for antiviral combination therapies in the area can be due to high incidence rates of HCV and HIV and increased market penetration by generic drug manufacturers. In addition, a huge pool of chronic disease patients in countries such as China and India and a large retail pharmacy network are contributing to the growth of the antiviral combination therapy market in Asia Pacific.

Global Antiviral Combination Therapies Market: Competitive Players

The major players in the global antiviral combination therapies market include Celltrion, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, AbbVie, Inc., Janssen Global Services, LLC, Bristol-Myers Squibb Company, Cipla, Inc., Merck & Co., Inc., Mylan N.V., and F. Hoffmann-La Roche Ltd. among others.

The report segment of global antiviral combination therapies market are as follows:

Global Antiviral Combination Therapies Market: Drug Combination Segment Analysis

• NTRI/NNRTI
• NRTI/Protease Inhibitor
• Integrase Inhibitor/NRTI
• Others

Global Antiviral Combination Therapies Market: Indication Segment Analysis

• HIV
• Hepatitis
• Others

Global Antiviral Combination Therapies Market: Distribution Channel Segment Analysis

• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Antiviral Combination Therapies Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table Of Content

• Chapter 1. Preface
  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & Offerings
  • 1.2. Research Scope
  • 1.3. Research Methodulogy
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodulogy
    • 1.3.3. Level 1: Primary Research
    • 1.3.4. Level 2: Secondary Research
    • 1.3.5. Level 3: Data Validation and Expert Panel Assessment Report Description and Scope
• Chapter 2. Executive Summary
  • 2.1. Global Antiviral Combination Therapies Market, 2016-2026, (USD Billion)
  • 2.2. Antiviral Combination Therapies Market: Market snapshot
• Chapter 3. Global Antiviral Combination Therapies Market – Industry Analysis
  • 3.1. Introduction
  • 3.2. Industry ecosystem analysis
  • 3.3. Technulogy landscape
  • 3.4. Market Drivers
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. MEA
  • 3.5. Restraints
  • 3.6. Opportunity
  • 3.7. Innovation & sustainability
  • 3.8. Regulatory landscape
  • 3.9. Porter’s Five Forces Analysis
  • 3.10. PESTLE Analysis
  • 3.11. Antiviral Combination Therapies Market: Market Attractiveness Analysis
    • 3.11.1. Market Attractiveness Analysis by Drug Combination Segment
    • 3.11.2. Market Attractiveness Analysis by Indication Segment
    • 3.11.3. Market Attractiveness Analysis by Distribution Channel Segment
• Chapter 4. Global Antiviral Combination Therapies Market - Competitive Landscape
  • 4.1. Company Market Share Analysis, 2019
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions and Mergers
    • 4.2.2. New Product Launch
    • 4.2.3. Agreements, Partnerships, Cullaborations and Joint Ventures
    • 4.2.4. Research & Development and Regional Expansion
• Chapter 5. Antiviral Combination Therapies Market – Drug Combination Segment Analysis
  • 5.1. Global Antiviral Combination Therapies Market Revenue Share, by Drug Combination, 2019 & 2026 (USD Billion)
  • 5.2. Global Antiviral Combination Therapies Market by NTRI/NNRTI, 2016 – 2026 (USD Billion)
  • 5.3. Global Antiviral Combination Therapies Market by NRTI/Protease Inhibitor, 2016 – 2026 (USD Billion)
  • 5.4. Global Antiviral Combination Therapies Market by Integrase Inhibitor/NRTI, 2016 – 2026 (USD Billion)
  • 5.5. Global Antiviral Combination Therapies Market by Others, 2016 – 2026 (USD Billion)
• Chapter 6. Antiviral Combination Therapies Market – Indication Segment Analysis
  • 6.1. Global Antiviral Combination Therapies Market Revenue Share, by Indication, 2019 & 2026 (USD Billion)
  • 6.2. Global Antiviral Combination Therapies Market by HIV, 2016 – 2026 (USD Billion)
  • 6.3. Global Antiviral Combination Therapies Market by Hepatitis, 2016 – 2026 (USD Billion)
  • 6.4. Global Antiviral Combination Therapies Market by Others, 2016 – 2026 (USD Billion)
• Chapter 7. Antiviral Combination Therapies Market – Distribution Channel Segment Analysis
  • 7.1. Global Antiviral Combination Therapies Market Revenue Share, by Distribution Channel, 2019 & 2026 (USD Billion)
  • 7.2. Global Antiviral Combination Therapies Market by Hospital Pharmacies, 2016 – 2026 (USD Billion)
  • 7.3. Global Antiviral Combination Therapies Market by Retail Pharmacies, 2016 – 2026 (USD Billion)
  • 7.4. Global Antiviral Combination Therapies Market by Others, 2016 – 2026 (USD Billion)
• Chapter 8. Antiviral Combination Therapies Market - Regional Analysis
  • 8.1. Global Antiviral Combination Therapies Market: Regional Overview
    • 8.1.1. Global Antiviral Combination Therapies Market Revenue Share, By Region, 2019 & 2026 (USD Billion)
  • 8.2. North America
    • 8.2.1. North America Antiviral Combination Therapies Market Revenue 2016 – 2026 (USD Billion)
    • 8.2.2. North America Antiviral Combination Therapies Market Revenue, By Drug Combination, 2016 – 2026 (USD Billion)
    • 8.2.3. North America Antiviral Combination Therapies Market Revenue, By Indication, 2016 – 2026 (USD Billion)
    • 8.2.4. North America Antiviral Combination Therapies Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.2.5. U.S.
      • 8.2.5.1. U.S. Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.2.5.2. U.S. Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.2.5.3. U.S. Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.2.6. Canada
      • 8.2.6.1. Canada Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.2.6.2. Canada Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.2.6.3. Canada Education & Learning Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.2.7. Mexico
      • 8.2.7.1. Mexico Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.2.7.2. Mexico Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.2.7.3. Mexico Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Antiviral Combination Therapies Market Revenue 2016 – 2026 (USD Billion)
    • 8.3.2. Europe Antiviral Combination Therapies Market Revenue, By Drug Combination, 2016 – 2026 (USD Billion)
    • 8.3.3. Europe Antiviral Combination Therapies Market Revenue, By Indication, 2016 – 2026 (USD Billion)
    • 8.3.4. Europe Antiviral Combination Therapies Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.3.5. UK
      • 8.3.5.1. UK Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.3.5.2. UK Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.3.5.3. UK Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.3.6. France
      • 8.3.6.1. France Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.3.6.2. France Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.3.6.3. France Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.3.7. Germany
      • 8.3.7.1. Germany Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.3.7.2. Germany Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.3.7.3. Germany Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.3.8. Italy
      • 8.3.8.1. Italy Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.3.8.2. Italy Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.3.8.3. Italy Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.3.9. Spain
      • 8.3.9.1. Spain Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.3.9.2. Spain Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.3.9.3. Spain Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.3.10. Russia
      • 8.3.10.1. Russia Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.3.10.2. Russia Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.3.10.3. Russia Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.3.11. Rest of Europe
      • 8.3.11.1. Rest of Europe Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.3.11.2. Rest of Europe Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.3.11.3. Rest of Europe Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Antiviral Combination Therapies Market Revenue 2016 – 2026 (USD Billion)
    • 8.4.2. Asia Pacific Antiviral Combination Therapies Market Revenue, By Drug Combination, 2016 – 2026 (USD Billion)
    • 8.4.3. Asia Pacific Antiviral Combination Therapies Market Revenue, By Indication, 2016 – 2026 (USD Billion)
    • 8.4.4. Asia Pacific Antiviral Combination Therapies Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.4.5. China
      • 8.4.5.1. China Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.4.5.2. China Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.4.5.3. China Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.4.6. Japan
      • 8.4.6.1. Japan Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.4.6.2. Japan Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.4.6.3. Japan Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.4.7. India
      • 8.4.7.1. India Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.4.7.2. India Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.4.7.3. India Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.4.8. Australia
      • 8.4.8.1. Australia Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.4.8.2. Australia Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.4.8.3. Australia Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.4.9. South Korea
      • 8.4.9.1. South Korea Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.4.9.2. South Korea Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.4.9.3. South Korea Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.4.10. Rest of Asia Pacific
      • 8.4.10.1. Rest of Asia Pacific Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.4.10.2. Rest of Asia Pacific Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.4.10.3. Rest of Asia Pacific Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Antiviral Combination Therapies Market Revenue 2016 – 2026 (USD Billion)
    • 8.5.2. Latin America Antiviral Combination Therapies Market Revenue, By Drug Combination, 2016 – 2026 (USD Billion)
    • 8.5.3. Latin America Antiviral Combination Therapies Market Revenue, By Indication, 2016 – 2026 (USD Billion)
    • 8.5.4. Latin America Antiviral Combination Therapies Market Revenue, By Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.5.5.2. Brazil Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.5.5.3. Brazil Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.5.6. Argentina
      • 8.5.6.1. Argentina Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.5.6.2. Argentina Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.5.6.3. Argentina Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.5.7. Rest of Latin America
      • 8.5.7.1. Rest of Latin America Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.5.7.2. Rest of Latin America Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.5.7.3. Rest of Latin America Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
  • 8.6. Middle East & Africa
    • 8.6.1. Middle East & Africa Antiviral Combination Therapies Market Revenue 2016 – 2026 (USD Billion)
    • 8.6.2. Middle East & Africa Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
    • 8.6.3. Middle East & Africa Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
    • 8.6.4. Middle East & Africa Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.6.5. GCC Countries
      • 8.6.5.1. GCC Countries Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.6.5.2. GCC Countries Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.6.5.3. GCC Countries Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.6.6. South Africa
      • 8.6.6.1. South Africa Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.6.6.2. South Africa Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.6.6.3. South Africa Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
    • 8.6.7. Rest of MEA
      • 8.6.7.1. Rest of MEA Antiviral Combination Therapies Market Revenue, by Drug Combination, 2016 – 2026 (USD Billion)
      • 8.6.7.2. Rest of MEA Antiviral Combination Therapies Market Revenue, by Indication, 2016 – 2026 (USD Billion)
      • 8.6.7.3. Rest of MEA Antiviral Combination Therapies Market Revenue, by Distribution Channel, 2016 – 2026 (USD Billion)
• Chapter 9. Company Profiles
  • 9.1. Celltrion, Inc.
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Product portfulio
    • 9.1.4. Business strategy
    • 9.1.5. Recent developments
  • 9.2. *Same information will be provided for below mentioned companies*
    • 9.2.1. Gilead Sciences, Inc.
    • 9.2.2. GlaxoSmithKline plc
    • 9.2.3. AbbVie, Inc.
    • 9.2.4. Janssen Global Services, LLC
    • 9.2.5. Bristul-Myers Squibb Company
    • 9.2.6. Cipla, Inc.
    • 9.2.7. Merck & Co., Inc.
    • 9.2.8. Mylan N.V.
    • 9.2.9. F. Hoffmann-La Roche Ltd.
    • 9.2.10. Others

Methodology